Evidence map›Paper›PMID 41140281›Full record

ReviewJournal of cell science2025

Tackling ciliary specialization to understand phenotypic variability in human primary ciliopathies.

Ruxandra Bachmann-Gagescu, John A Sayer

Abstract readReview
In one paragraph

Review in Journal of cell science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ruxandra Bachmann-GagescuDepartment of Molecular Life Sciences, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0002-3571-5271
John A SayerBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK.ORCID 0000-0003-1881-3782

Funding

European Union's Horizon Europe 101080717Kidney Research UK Paed_RP_001_20180925Kidney Research UK RP_007_20210729LifeArcMedical Research Council MR/Y007808/1Northern Counties Kidney Research Fund 20/01Swiss National Science Foundation 310030_220012Swiss National Science Foundation 31RD30_213722Swiss National Science Foundation EJP-RD2022Universität Zürich
6 · The paper itself

Abstract

Primary cilia are crucial cellular organelles with vital roles in signal transduction and cellular function. Disruptions in primary ciliary structure or function underlie a group of genetic disorders known as primary ciliopathies. These disorders present as a diverse range of clinical features with prominent phenotypic variability, often complicating their diagnosis and the basic understanding of their underlying molecular mechanisms. To grasp this complexity, the ciliopathy field is moving from a static view of primary cilia towards a more comprehensive understanding of their dynamic and specialized cell-type-specific roles. By building on the large amount of knowledge gathered over the past decades and by employing recently developed tools, including multi-omics and human cell-based in vitro models, we can now interrogate ciliary specialization to understand the role of cilia in each tissue and the consequences of ciliary gene dysfunction on human health. This Perspective explores the current challenges and opportunities associated with these modern tools and databases, highlighting important action points to advance our understanding of this fascinating organelle and its role in human health and disease.

Indexed as

CiliaCiliopathiesHumansPhenotypeSignal TransductionCell-type-specific ciliary specializationFibro-cystic kidney diseaseiPSC-derived modelsMulti-omicsNeurodevelopmental ciliopathiesOrganoidsPhenotypic heterogeneityPrimary ciliaRetinal dystrophies

Identifiers

PMID41140281
PMCPMC12633738

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.